Parmax Pharma Ltd

Parmax Pharma has experienced fluctuating financial performance, with net sales increasing from 11.05 Cr in Mar'24 to 28.20 Cr in Mar'25, but facing ongoing profitability challenges, including negative profits after tax of -2.09 Cr in Mar'25 and deteriorating reserves of -6.44 Cr. Despite revenue growth, the company struggles with liquidity and a rising debt burden.

Parmax Pharma's historical performance shows fluctuating net sales, increasing from INR 11.05 crore in March 2024 to INR 28.20 crore in March 2025, but it continues to face profitability challenges with negative profit before tax and reserves. Despite growth in sales, the company reported an operating profit of INR 0.25 crore in March 2025, recovering from a loss the previous year.

As of 07-Nov, Parmax Pharma Ltd's stock price is declining at 32.60, down 1.21%, and has fallen 6.19% over the last three days. It is trading below all major moving averages, with a significant drop in delivery volume, indicating a persistent downward trend compared to the broader market.

As of 31-Oct, Parmax Pharma Ltd's stock price is Rs 34.50, up 7.81% today, but it has a year-to-date decline of 22.03%. While it has recently outperformed the Sensex, its long-term performance remains weak compared to the broader market.

As of 29-Oct, Parmax Pharma Ltd's stock price is Rs 31.05, down 10.39%, and has underperformed significantly with a year-to-date decline of 29.83%. The stock is trading below all major moving averages, indicating a bearish trend and a lack of investor interest.

As of 27-Oct, Parmax Pharma Ltd's stock price is at 34.99, up 6.0% today, but it has underperformed year-to-date with a decline of 20.93%. Despite recent gains and increased investor interest, the stock lags behind broader market performance.

As of 24-Oct, Parmax Pharma Ltd's stock price is Rs 32.31, down 7.02%, with significant underperformance compared to the sector and the benchmark Sensex. The company faces serious financial challenges, including a negative book value and declining sales, making it a strong sell despite increased investor participation.

As of 23-Oct, Parmax Pharma Ltd's stock price is at 34.75, up 16.85% today, reversing a two-day decline and outperforming its sector. Despite a negative year-to-date performance of -21.47%, the stock shows strong short-term gains and increased investor participation.

As of 20-Oct, Parmax Pharma Ltd's stock price is Rs 31.16, down 9.52%, significantly underperforming its sector and the broader market. The company faces weak fundamentals and a negative book value, contributing to a year-to-date decline of 29.58%.

As of 15-Oct, Parmax Pharma Ltd's stock price is Rs. 34.50, up 8.49% today despite significant volatility and a year-to-date decline of -22.03%. While it has outperformed its sector recently, declining investor participation raises concerns about sustained interest in the stock.

As of 29-Sep, Parmax Pharma Ltd's stock price is at 33.05, down 1.93%, and has underperformed its sector today. The stock is in a bearish trend, trading below all key moving averages, with a significant drop in delivery volume and a year-to-date decline of 25.31%.

As of 25-Sep, Parmax Pharma Ltd's stock price is Rs 33.93, up 4.08% today, but it has declined 4.42% over the past month and 23.32% year-to-date. The company's financial health is weak, with negative indicators and significant underperformance compared to the market.

As of 04-Sep, Parmax Pharma Ltd's stock is priced at 36.20, up 2.52% today, but has declined 18.19% year-to-date and shows weak long-term fundamentals, indicating a risky investment. Despite a 9.70% return over the past year, it underperforms the broader market, raising concerns about its financial sustainability.

As of 26-Aug, Parmax Pharma Ltd is priced at 36.40, up 2.54%, but has underperformed recently with declines of 3.83% over the week and 3.63% over the month. Despite a 7.06% annual return, weak fundamentals and declining sales raise concerns about its long-term outlook.